NOVARTIS AG Form 6-K January 18, 2002

> SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

> > FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

Report on Form 6-K dated January 18, 2002

Novartis AG (Name of Registrant)

> Lichtstrasse 35 4056 Basel Switzerland

\_\_\_\_\_

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No X

Enclosure:

1. Invitation for the Full Year Results 2001 Presentation.

Investor Relations	Novartis International AG
	CH-4002 Basel
	Switzerland
	Karen J. Huebscher, Ph.D.
	Tel + 41 61 324 8433
	Nafida Bendali
	Tel + 41 61 324 3514
	Sabine Moravi, MBA
	Tel +41 61 324 8989

[NOVARTIS LOGO]

Silke Zentner Tel +41 61 324 8612 Francisco Bouzas Tel +41 61 324 2462 Fax +41 61 324 8444 Internet Address: http://www.novartis.com

- Full Year Results 2001 -

The Executive Committee of Novartis has great pleasure in inviting you to the presentation of the 2001 results and business developments. The meeting will take place on

Thursday, February 7, 2002 At 1.30 PM for a 2.00 PM prompt start at the Kongresszentrum in Basel

Messeplatz 21

Basel, Switzerland

Following the presentation, refreshments will be served.

We hope that you will be able to attend. Please find attached a reply form for your convenience.

- Reply form -

[ ] I will attend the Basel Presentation on February 7, 2002
[ ] I will follow the presentation on the Internet

First name	
Last name	
Company	
Address	
Fax	
E-mail	

Please send your response by mail or fax no later than February 1, 2002 to:

Novartis International AG Raquel Rodriguez Lichtstrasse 35 CH-4002 Basel Fax # +41 61 324 8444 E-mail: raquel.rodriguez@group.novartis.com

- Full Year Results 2001 webcast and dial-in numbers -

If you wish to follow our Full Year Results presentation as a webcast on the Internet, please use the following link: http://www.novartis.com/investors/index.shtml

If you prefer to dial into the conference through a telephone line we also offer the following dial-in numbers. The presentations will be available on the website and least 1 hour prior to the start of the event.

Date:	Thursday, February 7, 20	02
Time:	Advisable: dial-in 15 m 2.00 p.m. Switzer 1.00 p.m. UK 8.00 a.m. New Yor	land
Phone numbers:	+41 (0) 848 22 41 11 +1 800 860 24 42	Europe USA

Playback for 72 hrs after the call commencing

Date:	Thursday, February 7, 20	02
Time:	6.00 p.m. (Switzerland) 5.00 p.m. (UK) 12.00 p.m. (New York)	
Phone numbers:	+41 (0) 848 72 25 00 +1 877 344 75 29	Europe USA
Code:	539#	

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Novartis AG

Date: January 18, 2002

By: /s/ RAYMUND BREU

Name: Raymund Breu Title: Chief Financial Officer